Preparing your results

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

A ubiquitin replacement strategy in human cells reveals distinct mechanisms of IKK activation by TNFalpha and IL-1beta.

Molecular cell | Oct 23, 2009

Lysine-63 (K63)-linked polyubiquitination has emerged as a mechanism regulating diverse cellular functions, including activation of the protein kinase IKK in the NF-kappaB pathways. However, genetic evidence for a key role of K63 polyubiquitination in IKK activation is lacking. Here, we devise a tetracycline-inducible RNAi strategy to replace endogenous ubiquitin with a K63R mutant in a human cell line. We demonstrate that K63 of ubiquitin and the catalytic activity of Ubc13, an E2 that catalyzes K63 polyubiquitination, are required for IKK activation by IL-1beta, but surprisingly, not by TNFalpha. We further show that IKK activation by TNFalpha requires Ubc5, which functions with the E3 cIAP1 to catalyze polyubiquitination of RIP1 not restricted to K63 of ubiquitin. These results indicate that distinct ubiquitin-dependent mechanisms are employed for IKK activation by different pathways. The ubiquitin replacement methodology described here provides a means to investigate the function of polyubiquitin topology in various cellular processes.

Pubmed ID: 19854138 RIS Download

Mesh terms: Biocatalysis | Enzyme Activation | Gene Knock-In Techniques | Genetic Techniques | Humans | I-kappa B Kinase | Inhibitor of Apoptosis Proteins | Interleukin-1beta | Lysine | Nuclear Pore Complex Proteins | Polyubiquitin | RNA-Binding Proteins | Tetracycline | Tumor Necrosis Factor-alpha | Ubiquitin | Ubiquitin-Conjugating Enzymes | Ubiquitination

Research resources used in this publication

None found

Research tools detected in this publication

None found

Data used in this publication

None found

Associated grants

  • Agency: NIGMS NIH HHS, Id: R01-GM63692
  • Agency: NIAID NIH HHS, Id: F32 AI009919
  • Agency: NIGMS NIH HHS, Id: T32 GM007062
  • Agency: NIAID NIH HHS, Id: R01-AI09919
  • Agency: NIGMS NIH HHS, Id: R01 GM063692-08
  • Agency: NIGMS NIH HHS, Id: R01 GM063692
  • Agency: Howard Hughes Medical Institute, Id: GM007062
  • Agency: NIGMS NIH HHS, Id:

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

We have not found any resources mentioned in this publication.